

CORRECTION

Open Access



Correction to: Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Tao Zhang^{1†}, Rong Qu^{1†}, Shingpan Chan^{2†}, Mengzhen Lai^{1,3}, Linjiang Tong¹, Fang Feng¹, Hongyu Chen⁴, Tingting Song⁴, Peiran Song¹, Gang Bai^{1,5,6}, Yingqiang Liu^{1,3}, Yanan Wang¹, Yan Li¹, Yi Su¹, Yanyan Shen¹, Yiming Sun¹, Yi Chen¹, Meiyu Geng¹, Ke Ding^{2*}, Jian Ding^{1*} and Hua Xie^{1*}

Correction to: *Mol Cancer* 19, 90 (2020)

<https://doi.org/10.1186/s12943-020-01202-9>

Following the publication of the original paper [1], the authors found minor typographical errors that should be corrected.

In the Results section, the dosage of ASK120067 in the sentence “we present a preliminary result of a patient in this clinical study with a confirmed radiographic response after treatment with the lowest dose (40 mg/kg once daily)” has been corrected to “...with the lowest dose (40 mg once daily)”.

In the figure legend of Figure 3g, the sentence “Computed tomography scans of the chest from a patient before and after treatment with 40 mg/kg ASK120067 in a phase I trial...” has been corrected to “...treatment with 40 mg ASK120067 once daily in a phase I trial...”.

These corrections have no impact on the results or conclusions of the study.

The original article has been corrected.

Author details

¹Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China. ²International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemistry Drug Development, School of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou 510632, China. ³School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, China. ⁴Jiangsu Aosaikang Pharmaceutical Co.Ltd (ASK pharm), 699 Kejian Road, Nanjing 211112, China. ⁵University of Chinese Academy of Sciences, 19A Yuquan Road, Beijing 100049, China. ⁶School of Life Science and Technology, ShanghaiTech University, 393 Middle Huaxia Road, Shanghai 201210, China.

The original article can be found online at <https://doi.org/10.1186/s12943-020-01202-9>.

*Correspondence: dingke@jnu.edu.cn; jdjing@simm.ac.cn; hxie@simm.ac.cn

[†]Tao Zhang, Rong Qu, and Shingpan Chan contributed equally to this work.

¹ Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China

² International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemistry Drug Development, School of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou 510632, China
Full list of author information is available at the end of the article

Published online: 17 August 2021

Reference

1. Zhang T, Qu R, Chan S, et al. Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. *Mol Cancer*. 2020;19:90. <https://doi.org/10.1186/s12943-020-01202-9>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.